Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Polyunsaturated Fatty Acids in Children and Adolescents With Attention Deficit/ Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written Informed Consent by parents and patients (separately for age groups 6 - 11 years and 12 - 17 years)~* Children and adolescents of both gender in the age group between 6 and 17 years~* Confirmed diagnosis of ADHD by semi-structured clinical interview Kiddie Schedule for Affective Disorders and Schizophrenia for school-age children (K-SADS)~* ADHDRS-IV-Parent Version (18-Item-Scale): Investigator Administered and Scored ≥24~* Sufficient knowledge of the German language~Exclusion Criteria:~* Known hypersensitivity against components of either the verum or placebo food~* All serious internal diseases~* All severe psychiatric diseases except oppositional defiant disorders~* Current intake of the following medication: antidepressants and other psychotropic medication~* Recent intake of ω-3 fatty acids supplementation~* Indication for hospitalization~* Suicidality (including suicidal thoughts)~* intelligence quotient \< 70~* Previous medication with stimulants within 4 weeks~* Placement in an institution on official or judicial ruling~* Lack of willingness to store and transmit pseudonym data according to German regulations~* Parallel participation in another trial, or less than 4 weeks ago~* Patients foreseeable requiring a primary medication with methylphenidate during the study period of 12 weeks

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- ω-3 fatty acids suspension (Type: ACTIVE_COMPARATOR): 2 bags of Esprico(R) suspension each day. Each 4ml suspension bag includes 400mg eicosapentaenoic acid (EPA), 40mg docosahexaenoic acid (DHA), 5.4 mg gamma-linolenic acid (GLA), 80 mg magnesium, 5 mg zinc and consists of linseed oil, xylitol, sea fish oil with high portion of omega-3-acids, magnesium citrate, vegetable oil, orange flavour, evening primrose oil, zink gluconate, soya lecithin, citric acid, acesulfame k (E950)
- placebo suspension (Type: PLACEBO_COMPARATOR): 2 bags of Esprico (R) placebo suspension. Includes no ω-3 fatty acids, no ω-6 fatty acids, no magnesium and no zinc, but other vegetable oils, orange flavor, etc.

Based on this trial design, predict the completion outcome and termination type (if applicable).